A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus
Sponsor: Carmot Australia First Pty Ltd
Listed as NCT04838405, this PHASE1 trial focuses on Diabetes and remains completed. Sponsored by Carmot Australia First Pty Ltd, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
-
Mar 2025 — Nov 2025 [monthly]
Completed PHASE1
-
Oct 2024 — Mar 2025 [monthly]
Completed PHASE1
Status: Unknown → Completed
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
▶ Show 3 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE1
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Carmot Australia First Pty Ltd
- Carmot Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .